Eli Lilly’s Drug Likely To Dominate Global Obesity Market: Report
Zepbound, is more effective in promoting weight loss compared to the other wightloss drugs available in the market
Eli Lilly’s Drug Likely To Dominate Global Obesity Market: Report
New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday.
The drug will likely dominate the obesity market, surpassing Novo Nordisk’s Wegovy (semaglutide), according to GlobalData, a leading data and analytics company.
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues.
“From the start, Zepbound emerged as the primary new competitor of Wegovy, and it seems that Eli Lilly has followed in some way Novo Nordisk’s strategy to increase patients’ population through investigating the drug in multiple indications,” said Costanza Alciati, pharma analyst at GlobalData.
Recently, Eli Lilly announced the results from its SURMOUNT-5 trial, comparing Zepbound and Wegovy’s efficacy on equal grounds.
Zepbound, as expected, was more effective in promoting weight loss. While Wegovy caused an average weight loss of 13.7 per cent body weight, Zepbound promoted around 20.2 per cent body weight loss in patients.
On December 20, 2024, tirzepatide also received US FDA approval for obstructive sleep apnea.
